Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer.
dc.contributor.author | Busch, Susann | |
dc.contributor.author | Rydén, L | |
dc.contributor.author | Stål, O | |
dc.contributor.author | Jirström, K | |
dc.contributor.author | Landberg, Göran | |
dc.date.accessioned | 2012-12-13T14:50:54Z | |
dc.date.available | 2012-12-13T14:50:54Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer. 2012, 7 (9):e45669 PLoS ONE | en_GB |
dc.identifier.issn | 1932-6203 | |
dc.identifier.pmid | 23029174 | |
dc.identifier.doi | 10.1371/journal.pone.0045669 | |
dc.identifier.uri | http://hdl.handle.net/10541/262494 | |
dc.description.abstract | The aim of this study was to evaluate ERK phosphorylation as a stromal biomarker for breast cancer prognosis and tamoxifen treatment prediction within a randomized tamoxifen trial. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to PloS one | en_GB |
dc.title | Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer. | en |
dc.type | Article | en |
dc.contributor.department | Breakthrough Breast Cancer Research Unit, School of Cancer, Enabling Sciences and Technology, University of Manchester, Manchester Academic Health Science Centre, Paterson Institute for Cancer Research, The Christie NHS Foundation Trust, Manchester, United Kingdom. | en_GB |
dc.identifier.journal | PloS One | en_GB |
html.description.abstract | The aim of this study was to evaluate ERK phosphorylation as a stromal biomarker for breast cancer prognosis and tamoxifen treatment prediction within a randomized tamoxifen trial. |